Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-22-002477
Filing Date
2022-08-15
Accepted
2022-08-15 17:38:43
Documents
5

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 TO THE SCHEDULE 13D sc13da307004013_08152022.htm SC 13D/A 376915
2 ex991to13da307004013_081522.htm EX-99.1 10654
3 ex992to13da307004013_081522.htm EX-99.2 8580
4 ex993to13da307004013_081522.htm EX-99.3 86740
5 GRAPHIC image_001.jpg GRAPHIC 5553
  Complete submission text file 0000921895-22-002477.txt   492387
Mailing Address 23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS CA 92653
Business Address 23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS CA 92653 (917) 595.2850
PharmaCyte Biotech, Inc. (Subject) CIK: 0001157075 (see all company filings)

EIN.: 621772151 | State of Incorp.: NV | Fiscal Year End: 0430
Type: SC 13D/A | Act: 34 | File No.: 005-91495 | Film No.: 221167025
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 641 LEXINGTON AVENUE 26TH FLOOR NEW YORK, NY 10022
Business Address 641 LEXINGTON AVENUE 26TH FLOOR NEW YORK, NY 10022 212.974.3070
Iroquois Capital Management, LLC (Filed by) CIK: 0001481867 (see all company filings)

EIN.: 010786483 | State of Incorp.: DE
Type: SC 13D/A